Repare Therapeutics Inc. has announced a strategic partnership with DCx Biotherapeutics Corporation through an out-licensing agreement. Under this collaboration, Repare will transfer its discovery platforms and certain intellectual property to DCx, a newly-launched Canadian biotechnology firm. The agreement includes upfront and near-term payments totaling $4 million to Repare and grants them a 9.99% equity stake in DCx. Additionally, Repare is eligible for future milestone payments and sales royalties. This partnership allows Repare to concentrate on its clinical portfolio while maintaining an economic interest in the technologies developed. DCx will also acquire lease rights to laboratory facilities in Montreal and retain approximately 20 of Repare's preclinical research employees.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。